AnaptysBio, Inc. (ANAB) financial statements (2020 and earlier)

Company profile

Business Address 10421 PACIFIC CENTER COURT, SUITE 200
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments374421422416427494268
Cash and cash equivalents17118314710611429357
Short-term investments203238276310313200211
Receivables  5  5 
Other undisclosed current assets4446744
Total current assets:378425431422434503272
Noncurrent Assets
Property, plant and equipment2212111
Long-term investments and receivables54234669731933
Long-term investments54234669731933
Restricted cash and investments0000000
Other noncurrent assets1222000
Total noncurrent assets:57274972752034
TOTAL ASSETS:435452480494509523306
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2726251714139
Accounts payable1611119564
Accrued liabilities1115148975
Debt1356888
Other liabilities1111000
Total current liabilities:30303125222117
Noncurrent Liabilities
Long-term debt and lease obligation    124
Long-term debt, excluding current maturities    124
Liabilities, other than long-term debt1111000
Accounts payable and accrued liabilities    000
Other liabilities1111   
Total noncurrent liabilities:1111134
Total liabilities:30313226232321
Stockholders' equity
Stockholders' equity attributable to parent405421448468486500285
Common stock0000000
Additional paid in capital649644641637633630399
Accumulated other comprehensive income (loss)0010(0)(1)(1)
Accumulated deficit(244)(224)(193)(169)(147)(130)(114)
Total stockholders' equity:405421448468486500285
TOTAL LIABILITIES AND EQUITY:435452480494509523306

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Gross profit:3 5  5 
Operating expenses(25)(34)(32)(25)(20)(22)(14)
Operating loss:(22)(34)(27)(25)(20)(17)(14)
Nonoperating income2333211
Interest and debt expense(0)(0)(0)(0)(0)(0)(0)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes(1)000   
Loss from continuing operations before equity method investments, income taxes:(21)(31)(24)(22)(18)(16)(14)
Other undisclosed income from continuing operations before income taxes1   2  
Loss from continuing operations before income taxes:(20)(31)(24)(22)(16)(16)(14)
Income tax benefit0000   
Other undisclosed income from continuing operations    0  
Net loss:(20)(31)(24)(22)(16)(16)(14)
Other undisclosed net income (loss) attributable to parent    (1)00
Net loss available to common stockholders, diluted:(20)(31)(24)(22)(17)(16)(14)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(20)(31)(24)(22)(16)(16)(14)
Other comprehensive income (loss) (0)00   
Other undisclosed comprehensive income    0  
Comprehensive loss:(20)(31)(24)(22)(16)(16)(14)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)   (1)11
Comprehensive loss, net of tax, attributable to parent:(20)(31)(24)(22)(17)(16)(13)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: